Results 21 to 30 of about 6,491 (191)

Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study. [PDF]

Pediatr Pulmonol
ABSTRACT Introduction New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers.
Rose A, Datta RR, Di Chiara C, Piché-Renaud PP, Morris SK.   +4 more
europepmc   +2 more sources

Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention. [PDF]

Pediatr Investig
Pediatric Investigation, Volume 10, Issue 4, Page 293-299, August 2026.
Wang R, Abu-Raya B, Obeid H, Xie Z.
europepmc   +2 more sources

Does Prophylaxis Against Respiratory Syncytial Virus Infection Affect the Weight Percentiles of Infants with Hemodynamically Significant Congenital Heart Disease?

Journal of Behçet Uz Children's Hospital, 2021
Objective: The risk of severe respiratory syncytial virus (RSV) infection with significant morbidity and mortality is greatest in patients with hemodynamically significant congenital heart disease (hs-CHD). The humanized monoclonal antibody, palivizumab,
Ali Orgun, İbrahim İlker Çetin, Hazım Alper Gürsu   +2 more
doaj   +1 more source

Linking pharmacy dispensing data to other administrative health datasets to measure the compliance and effectiveness of RSV immunoprophylaxis

International Journal of Population Data Science, 2018
Introduction Respiratory Syncytial Virus (RSV) causes considerable morbidity in children. RSV vaccines are in development, but the only current preventive measure is immunoprophylaxis with monoclonal antibody, palivizumab.
Hannah Moore, Tobias Strunk, Tasnim Abdalla, Tom Snelling, Peter Richmond, Anthony Keil, Nicholas de Klerk   +6 more
doaj   +1 more source

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BMC Pediatrics, 2020
Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV).
Ruomei Xu, Parveen Fathima, Tobias Strunk, Nicholas de Klerk, Thomas L. Snelling, Peter C. Richmond, Anthony D. Keil, Hannah C. Moore   +7 more
doaj   +1 more source

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study

Italian Journal of Pediatrics, 2023
Background In children with congenital heart disease (CHD) respiratory syncytial virus (RSV) infection may have a severe course, with increased risk of morbidity and mortality, requiring hospital admission and intensive care. The aim of the present study
Chiara Ratti, Anna della Greca, Deborah Bertoncelli, Monica Rubini, Bertrand Tchana   +4 more
doaj   +1 more source

Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge [PDF]

, 2018
BACKGROUND:Palivizumab provides passive immunity for respiratory syncytial virus (RSV), but poor adherence compromises protection. A hospital initiative promoted administration of first palivizumab doses at an outpatient clinic immediately after ...
Chen, Yanjun, Stockton, Winifred, Chilvers Murphy, Michelle, Lee, Tina, Allison Jun, Magedman, Grace, Tina Lee, Jun, Allison, Yanjun Chen, Grace Magedman, Michelle Chilvers Murphy, Winifred Stockton   +11 more
core   +1 more source

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010

Emerging Infectious Diseases, 2012
To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006–2010.
Jesse Papenburg, Julie Carbonneau, Marie-Ève Hamelin, Sandra Isabel, Xavier Bouhy, Najwa Ohoumanne, Pierre Déry, Bosco A. Paes, Jacques Corbeil, Michel G. Bergeron, Gaston De Serres, Guy Boivin   +11 more
doaj   +1 more source

Palivizumab Administration Decreases Recurrent Wheeze [PDF]

, 2014
Children who have been infected with Respiratory Syncytial Virus have a higher incidence of wheeze-associated clinic visits and hospitalizations compared to children without previous RSV exposure. The purpose of this study is to determine if palivizumab,
Daniels, Shelly
core   +1 more source

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia

Journal of Allergy and Clinical Immunology: Global, 2023
Background: Infants with respiratory-syncytial virus bronchiolitis hospitalization are more likely to develop wheezing and subsequent asthma. Reportedly, palivizumab prophylaxis effectively prevents respiratory-syncytial virus hospitalization in high ...
Li-Ching Fang, MD, Jen-Yu Wang, MD, Hsin-Hui Yu, MD, PhD, Li-Chieh Wang, MD, PhD, Bor-Luen Chiang, MD, PhD   +4 more
doaj   +1 more source